Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma
Introduction
Annually there are 22,220 new cases of ovarian cancer in the United States and 16,210 deaths [1]. Despite efforts to develop an effective ovarian cancer screening method, 60% of patients still present with advanced (Stages III–IV) disease [2]. In the setting of primary disease, optimal cytoreductive surgery (< 1–2 cm) and platinum-based chemotherapy have been established as the most important components when treating advanced epithelial ovarian cancer [3], [4], [5], [6], [7]. The theoretic benefit from cytoreductive surgery relates to removing large tumor volumes that have a decreased growth fraction and poor blood supply, thereby improving the efficacy of chemotherapeutic agents [8].
Despite achieving clinical remission after completion of initial treatment, most patients (60%) with advanced epithelial ovarian cancer will ultimately develop recurrent disease [9]. The management of recurrent ovarian cancer is less clear than that of primary disease. Available literature regarding secondary cytoreductive surgery is largely composed of retrospective studies and, more recently, several prospective studies [10], [11], [12]. Several studies have concluded that patients with platinum-resistant disease (recurrent disease within 6 months of completing treatment) do not benefit from secondary cytoreductive surgery [13], [14]. Multiple other preoperative and operative factors have been evaluated to help delineate which patients will benefit from secondary cytoreductive surgery, but clear criteria for selection of patients remain unclear. This study was performed to help delineate factors that would improve survival in patients being evaluated for secondary cytoreduction. In addition, surgical procedures and complications are being reported so that appropriate preoperative counseling of patients can occur. Finally, from these patients for whom cytoreduction is determined to be beneficial, we hope to determine which operative factors influence survival.
Section snippets
Materials and methods
Institutional review board approval was obtained prior to initiating the study. Patients who underwent cytoreduction for recurrent ovarian cancer were identified from our gynecologic oncology surgical database for the period 1988–2004. Selection criteria for secondary cytoreductive surgery during the study interval included a disease-free interval ≥ 6 months, a Gynecologic Oncology Group performance status ≤ 2, radiographic and physical exam findings of an isolated site of recurrence, and absence
Results
During the study period, 85 patients met eligibility criteria. The mean age was 61 years (range 35–87 years). Most patients were Caucasian (96%) and the mean body mass index was 24.6 kg/m2 (range 19–46 kg/m2). Comorbid medical conditions such as hypertension, diabetes, and coronary artery disease were present in 35% of patients. In our population, a personal history of breast and uterine cancer was reported in 10% and 5% of patients, respectively. Twenty percent of patients reported a family
Conclusion
A consensus regarding the management of recurrent epithelial ovarian cancer, especially the role of secondary cytoreductive surgery, has yet to be reached. Much of the research is retrospective in nature and limited to small series [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30].
More recently, several prospective studies have evaluated factors influencing survival in patients undergoing secondary cytoreductive surgery further clarifying and
References (30)
- et al.
Critical evaluation of secondary cytoreduction in recurrent ovarian cancer
Gynecol. Oncol.
(2004) - et al.
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
Am. J. Obstet. Gyneol.
(1994) - et al.
Stage III epithelial ovarian cancer: the role of maximal surgical reduction
Gynecol. Oncol.
(1984) - et al.
Secondary cytoreductive surgery for ovarian cancer
Obstet. Gynecol. Clin. North Am.
(1994) - et al.
Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma
Gynecol. Oncol.
(2001) - et al.
Secondary cytoreductive surgery in epithelial ovarian cancer: non responders to first-line therapy
Gynecol. Oncol.
(1989) - et al.
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
Gynecol. Oncol.
(1989) - et al.
Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response
Gynecol. Oncol.
(1995) - et al.
Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer
Gynecol. Oncol.
(2000) - et al.
Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer
Eur. J. Surg. Oncol.
(2000)
Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer
Gynecol. Oncol.
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
Obstet. Gynecol.
Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum
Eur. J. Surg. Oncol.
The role of secondary cytoreductive surgery for recurrent ovarian cancer
Gynecol. Oncol.
The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience
Am. J. Obstet. Gynecol.
Cited by (64)
Isolated lymph node recurrence in epithelial ovarian cancer – management and outcome
2023, Journal of Visceral SurgerySecondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement
2021, Gynecologic OncologySecondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study
2014, European Journal of Surgical OncologyInvolved-field radiation therapy for locoregionally recurrent ovarian cancer
2013, Gynecologic Oncology